Basiliximab (Simulect®)

  • Prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adults
  • A chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells
  • Intravenous injection: 10mg and 20mg vials
  • Hypersensitivity to the active substance or to any of the excipients
  • Pregnancy and lactation - women advised to use effective contraception for up to 16 weeks after treatment
  • Use with caution in patients who have previously had basiliximab due to increased risk of developing hypersensitivity reactions
  • Hypersensitivity reactions are uncommon, but can occur within 24 hours and include rash, urticaria, wheezing, sneezing
  • Common side effects: constipation, UTI, pain, nausea, peripheral oedema, hypertension, anaemia, headache, hyperkalaemia, weight increase, increase in creatinine, hypophosphataemia, diarrhoea
  • There is an increased risk of lymphoproliferative disorders (LPDs; such as lymphoma) and opportunistic infections such as CMV
  • Adults and children >35kg: 20 mg within 2 hours prior to transplant surgery and 20 mg 4 days after surgery; withhold second dose if severe hypersensitivity or graft loss occurs
  • Reconstitute each vial with 5 mL water for injection then dilute to 50 mL or greater with sodium chloride 0.9% or glucose 5%
  • To be administered by intravenous bolus injection or by intravenous infusion over 20–30 minutes
Dose in renal impairment
  • No dose adjustments in renal impairment
  • Not dialysed
  • Because Basiliximab is an immunoglobulin → no metabolic drug-drug interactions are to be expected
  • May alter requirements for tacrolimus and ciclosporin
How to Prescribe View Details
Patient comment
  • Basiliximab must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression
  • Store in a refrigerator
  • Avoid live vaccines – ask your pharmacist
  • Increased risk of infection and cancer

Back to listing